RayzeBio Inc

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.

Bristol-Myers

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating pat.

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiratio.

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting peri.

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

Affirm

Apogee Therapeutics Inc

Instacart (Maplebear Inc.)

Confluent

Cargo Therapeutics Inc

Structure Therapeutics Inc

Palo Alto Networks

Snap

Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.

IPO watch 2024: Which new stocks will hit the market?

AbbVie

Amgen

AstraZeneca

Cerevel Therapeutics Holdings Inc

Horizon Pharma

ImmunoGen

Karuna Therapeutics Inc

Mirati Therapeutics

Pfizer

Roche Holding AG

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (NasdaqGM: RYZB) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of RayzeBio will receive $62.50 in cash for each share of RayzeBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

Fusion Pharmaceuticals

Eli Lilly

Point Biopharma Global

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options. It was the second multibillion-dollar acquisition for Bristol Myers Squibb in less than a week.

Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days

Intel

Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive territory.

Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio

Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has made its second major acquisition in the span of a week, this time buying cancer drug developer RayzeBio in a $4.1 billion deal.  The deal values RayzeBio at $62.50 per share.

Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

MILWAUKEE , Dec. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating RayzeBio (NASDAQ: RYZB) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers. Click here to learn how to join the https://www.ademilaw.com/case/rayzebio-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether RayzeBio, Inc. has obtained a Fair Price in its transaction with Bristol Myers

Shares in RayzeBio (NASDAQ: RYZB ) doubled after Bristol Myers Squibb (NYSE: BMY ) said it will buy it for about $4.1 billion. Bristol Myers is paying $62.50 per share for the cancer drug maker, which is based in San Diego.

Why Is RayzeBio (RYZB) Stock Up 100% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RayzeBio, Inc. (NASDAQ: RYZB) to Bristol-Myers Squibb Company for $62.50 per share in cash is fair to RayzeBio shareholders. Halper Sadeh encourages RayzeBio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Rayz.

RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.

Bristol Myers to buy RayzeBio for about $4.1B

Apple

Masimo

Nano Dimension

Stratasys

The holiday shopping season isn't over yet. A 3-D printing company and a major pharmaceuticals maker announced post-Christmas acquisitions Tuesday morning.

Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'

RayzeBio is a late-stage developer of radiotherapeutic products targeting solid tumors in oncology. Their lead asset, RYZ101, uses the 225Ac isotope to target gastroenteropancreatic neuroendocrine tumors (GEP-NETs) through the SSTR2 receptor. RYZ101 has shown promising results in a phase 1b study, with a confirmed overall response rate of 29% as of June 2023.

RayzeBio: New IPO With Good Data And Solid Premise

Dec 26 (Reuters) - Bristol Myers Squibb (BMY.N) said on Tuesday it would buy RayzeBio (RYZB.O) for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less than a week.

Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies

RayzeBio is being bought for $62.50 a share in cash.

Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers will pay $62.50 in cash for each RayzeBio share outstanding, which represents a premium of 104.4% over Friday's closing price of $30.57.

Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion

Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less than a week.

Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push

ARM Holdings PLC

Cava Group, Inc.

NEXTracker Inc

Oddity Tech Ltd

ACELYRIN Inc

After navigating treacherous waters in the preceding year, the US initial public offering (IPO) market embarked on a path of recovery in 2023, signaling the inception of a new upcycle.

The 2023 IPO scene: Biggest hits and misses

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company's management team will participate in the following investor conferences in November 2023:

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

News for RayzeBio Inc Stock (RYZB)